Genmab A/S's (GMAB) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB - Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $50.00 price objective on the stock.

A number of other research analysts have also recently issued reports on the stock. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a "buy" rating for the company. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. BTIG Research upped their target price on Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, June 27th. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.20.

Genmab A/S Stock Performance

GMAB traded down $0.58 during trading on Wednesday, reaching $22.60. The company's stock had a trading volume of 1,330,715 shares, compared to its average volume of 612,399. The company has a market capitalization of $14.95 billion, a price-to-earnings ratio of 18.83, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98. The company's fifty day moving average price is $25.96 and its 200-day moving average price is $27.21. Genmab A/S has a 52-week low of $22.52 and a 52-week high of $33.45.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Equities analysts predict that Genmab A/S will post 1.27 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of GMAB. Creative Planning raised its holdings in Genmab A/S by 136.3% in the 3rd quarter. Creative Planning now owns 47,422 shares of the company's stock valued at $1,156,000 after acquiring an additional 27,353 shares during the last quarter. Ritholtz Wealth Management purchased a new position in Genmab A/S during the third quarter worth about $314,000. Sanctuary Advisors LLC acquired a new stake in Genmab A/S in the 2nd quarter worth about $1,354,000. Point72 Asset Management L.P. purchased a new stake in Genmab A/S in the 2nd quarter valued at about $457,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock valued at $7,000,000 after acquiring an additional 145,689 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.